<!DOCTYPE html>
<!--ODETIGLUCAN-->
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Daelion Therapeutics - Odetiglucan Program</title>
  <link rel="stylesheet" href="../css/style.css" />
</head>
<body>
  <!-- Header -->
  <header>
    <div class="header-container">
      <div class="logo">
		  <a href="../index.html">
			<img src="../images/placeholder-logo.png" alt="Daelion Therapeutics Logo" />
		  </a>
      </div>
     <!-- Hidden checkbox toggle for mobile -->
    <input type="checkbox" id="menu-toggle" class="menu-toggle" />
    <label for="menu-toggle" class="hamburger">
      <span></span>
      <span></span>
      <span></span>
    </label>
	
      <nav id="main-nav" >
        <ul class="nav-links">
          <li class="dropdown">
            <a href = "#">About</a>
            <ul class="dropdown-content">
              <li><a href="../mission/index.html">Mission</a></li>
              <li><a href="../leadership/index.html">Leadership</a></li>
            </ul>
          </li>
          <li class="dropdown">
            <a href="../odetiglucan/index.html">Our Science</a>
          </li>
          <li class="dropdown">
            <a href="../pipeline/index.html">Pipeline</a>
          </li>
          <li class="dropdown">
            <a href="../patients-and-caregivers/index.html">Patients & Caregivers</a>
          </li>
          <li class="dropdown">
            <a href="../news-publications/index.html">News & Publications</a>
          </li>
          <li><a href="../contact/index.html">Contact</a></li>
        </ul>
      </nav>
    </div>
  </header>

  <!-- Hero Section with Image -->
<!--  <section class="hero">
    <img 
      src="../images/background_1.jpg" 
      alt="Immunotherapy Hero Image" 
      class="hero-image"
    />
    <div class="hero-overlay">
      <div class="hero-text">
        <h1>Odetiglucan Program</h1>
        <p>
          A first-in-class myeloid-directed immune modulator advancing through clinical trials to improve outcomes in multiple tumor types.
        </p>
      </div>
    </div>
  </section>
-->
<section class="hero">
  <div class="video-container">
    <video autoplay muted loop playsinline>
      <source src="../videos/background_1.mp4" type="video/mp4" />
      Your browser does not support the video tag.
    </video>
  </div>
  <div class="hero-overlay">
    <div class="hero-text">
      <h1>Odetiglucan Program</h1>
      <p>
        A first-in-class myeloid-directed immune modulator advancing through clinical trials to improve outcomes in multiple tumor types.
      </p>
    </div>
  </div>
</section>

  <main>
    <section class="content white-bg centered-text">
      <div class="section-container">
        <h2>Clinical Development of Odetiglucan</h2>
        <p>
          Odetiglucan, in combination with multiple therapies, has demonstrated encouraging clinical activity across diverse tumor histologies, including in patients with liver metastases. Odetiglucan is currently being evaluated in two Phase 2 
		  investigator-initiated clinical trials in combination with an immune checkpoint inhibitor and another myeloid agonist in patients with colorectal and pancreatic cancers.
        </p>
      </div>
    </section>

    <section class="side-by-side-section">
      <div class="section-container">
        <div class="text-wrapper">
          <h2>The Odetiglucan Immune Complex</h2>
          <p>
            Odetiglucan is an immune agonist that modulates both the innate and adaptive immune systems.  It forms an immune complex in vivo through three receptors - Dectin-1, FcɣR, and CR3 - resulting in the activation of anti-tumor immunity.
          </p>
          <p>
            Unlike many other PRR agonists (cGAS-STING, TLR, etc.), Odetiglucan has been clinically observed to be generally well-tolerated and suitable for systemic administration due to its non-inflammatory, chemokine-driven innate immune activation.  Consequently, Odetiglucan is not restricted to intratumoral injection and does not rely on an abscopal effect to achieve systemic immune modulation.
          </p>
          <p>
            Odetiglucan drives anti-tumor immunity by reprogramming the immunosuppressive tumor microenvironment, enhancing antigen presentation, priming a de-novo T cell responses, and inducing trained immunity to promote durable immune memory.
          </p>
        </div>
        <div class="image-wrapper">
          <img src="../images/odetiglucan.jpg" alt="Odetiglucan Immune Complex Image" />
        </div>
      </div>
    </section>
  </main>

  <!-- Footer -->
  <footer class="site-footer">
    <div class="footer-content">
      <div class="footer-logo">
        <img src="../images/placeholder-logo.png" alt="Daelion Therapeutics Logo" />
      </div>
      <p>© 2025 Daelion Therapeutics. All rights reserved.</p>
    </div>
  </footer>

  <script src="/js/script.js"></script>
</body>
</html>

